CA
NZ
UK
AU
IND
US
No new company release was found for November 2, 2026. The move follows a sharp week of news, and it appears to be a bounce after earlier weakness rather than a reaction to a fresh announcement.
No company press release or filing explaining the move was identified. The company has filed several Form 6-K reports in recent weeks, but their contents could not be confirmed in the sources reviewed, so they are not treated as the catalyst. The gain is …
On October 15, 2026 the company said an internal version of its Standard Gold platform, combining USD accounts, cards and allocated physical gold, was in team testing. The platform is not publicly available and banking partnerships are still being finalised.Market Capitalisationwas about USD 5.36 …
The company said its Louisiana portfolio totals about 5 GW in active development, including a nuclear project of up to 1 GW. As a penny stock, it carriesVolatilityand dilution risk, and nuclear projects face long permitting timelines.
The company said top-line data from the Phase 1 SLIM-1 trial of NPM-139, a semaglutide implant, are expected in November 2026. The study dosed 20 participants, ten on NPM-139 and ten on Wegovy for four weeks, so it is small. Cash was USD 20.8 …
The company will report third quarter 2026 results and host a call on November 9, 2026, with guidance of USD 29.5 million to USD 32.5 million in revenue. Second quarterRevenuewas USD 30.6 million, down 2 percent, and cash was USD 160.6 million at June …
The company completed a fixed wireless accessAcquisitionon October 1, 2026, which it expects to roughly double revenue. Full-year 2026Revenueguidance was cut to USD 155 million from USD 190 million. Third quarter guidance called for revenue of USD 28 million to USD 35 million, and …
The company began Nasdaq trading in late October 2026 after completing itsMergerwith a blank-check company. It develops atomic layer deposition equipment used on semiconductor wafers, filters, membranes and battery materials. At under USD 5 it is a penny stock, with a 52-week range of …
A prospectus supplement dated July 14, 2026 allows sales of up to USD 3.95 million of common stock through an at-the-market program, with no minimum sale required. Cash was approximately USD 1.0 million at fiscal year end, and the shares are now below USD …
The company said no other products are affected and that it is working with the FDA. It did not disclose a financial impact. A business update call was set for 8:30 a.m. ET on November 2, 2026, and third quarter fiscal 2026 results are …
Please wait processing your request...